Arrowhead Pharmaceuticals develops medicines for intractable diseases. Products include Plozasiran, Zodasiran, ARO-PNPLA3, ARO-RAGE, and others. These products are in various clinical trial phases, treating conditions such as hypertriglyceridemia, dyslipidemia, NASH, pulmonary conditions, IPF, FSHD, ALS, and kidney diseases. The company also develops JNJ-3989, Olpasiran, GSK-4532990, HZN-457, and Fazirsiran. Arrowhead has partnerships with Janssen, Takeda, Horizon, Amgen, and Glaxosmithkline. The company was founded in 2003 and is headquartered in Pasadena, California.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |